Filing Details

Accession Number:
0001209191-16-095840
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-02-04 18:51:22
Reporting Period:
2016-02-02
Filing Date:
2016-02-04
Accepted Time:
2016-02-04 18:51:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1557290 A Stuart Arbuckle C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Evp\Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-02-02 17,299 $0.01 121,763 No 4 A Direct
Common Stock Disposition 2016-02-03 2,597 $89.92 119,166 No 4 S Direct
Common Stock Disposition 2016-02-03 2,100 $90.98 117,066 No 4 S Direct
Common Stock Disposition 2016-02-03 700 $91.89 116,366 No 4 S Direct
Common Stock Disposition 2016-02-03 645 $92.80 115,721 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2016-02-02 34,482 $0.00 34,482 $91.05
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
34,482 2026-02-01 No 4 A Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 140 Indirect 401(k)
Footnotes
  1. Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $89.92 (range $89.31 to $90.27).
  3. Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $90.98 (range $90.38 to $91.32).
  5. Open market sales reported on this line occurred at a weighted average price of $91.89 (range $91.38 to $92.35).
  6. Open market sales reported on this line occurred at a weighted average price of $92.80 (range $92.40 to $93.03).
  7. The option vests in 16 quarterly installments from 02/02/2016.